Tesaglitazar (AZ 242) is a peroxisome proliferator-activated receptor agonist with affinity to PPARα and PPARγ proposed for type 2 diabetes.The drug had completed several phase III clinical trials however in May 2006 AstraZeneca announced that it had discontinued further development.
This page contains content from the copyrighted Wikipedia article "Tesaglitazar"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
